A cell surface receptor called Programmed Death-1 (PD-1) serves as a T cell checkpoint and is crucial in controlling T cell exhaustion. PDL-1 or PDL-2 engagement with PD-1 causes it to become active. When the PD-1 receptor binds to its ligands, PD-L1 and PD-L2, which are expressed on cancer cells and antigen-presenting cells, it sends inhibitory checkpoint signals to activated T cells. This suppresses T-cell effector function and allows tumor immune evasion. An appealing approach for tumor immunotherapy is to block the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway.
Activated T cells, B cells, monocytes, dendritic cells, regulatory T cells, and natural killer T cells all express PD-1. It belongs to a group of immunoglobulin domain (Ig) co-receptors that affect how the T cell receptor responds when activated by an antigen-presenting cell (APC) or an infected target cell. In contrast to PD-L2, which is only and inducibly expressed on professional APCs, PD-L1 is widely expressed and constitutively on both hematopoietic and nonhematopoietic cells, including naive T and B cells, vascular endothelial cells, and pancreatic islet cells.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V79414 | Finotonlimab (SCT-I10A) | Finotonlimab (SCT-I10A) is a recombinant humanized PD-1 antibody. | |
|
V76906 | Human PD-L1 inhibitor V TFA | Human PD-L1 inhibitor V TFA is a human PD-1 protein binding peptide with a Kd of 3.32 μM, which can inhibit the binding of human PD-1/PD-L1. | |
|
V78598 | LP23 | LP23 is a non-arylmethylamine PD-1/PD-L1 PPI inhibitor (IC50= 16.7 nM) with anti-tumor activity. | |
|
V51242 | MAX-10181 | 2171558-14-6 | PD-1/PD-L1 inhibitor |
|
V3255 | N-deacetylated BMS-202 | 2310135-18-1 | N-deacetylated BMS-202, the deacetylated product of BMS-202 (also known asPD1-PDL1 inhibitor 2,BMS 202, BMS202), is a inhibitor of the PD-1 (Programmed death- 1)/PD-Ll (Programmed death-ligand 1) protein/protein interaction with potential anticancer activities. |
|
V81058 | PD-1-IN-17 TFA | PD-1-IN-17 TFA is a potent programmed cell death-1 (PD-1) inhibitor. | |
|
V80590 | PD-1-IN-20 | PD-1-IN-20 is the less active enantiomer of PD-1-IN-1. | |
|
V81056 | PD-1/PD-L1-IN-31 | PD-1/PD-L1-IN-31 is a PD-1/PD-L1 PPI inhibitor (IC50=2.2 nM). | |
|
V76653 | PD-1/PD-L1-IN-9 hydrochloride | PD-1/PD-L1-IN-9 HCl is a potent and orally bioactive inhibitor of the PD-1/PD-L1 interaction with IC50 of 3.8 nM. | |
|
V79958 | PD-L1-IN-3 | PD-L1-IN-3 (Compound 4a) is a compound targeting PD-1/PD-L1. | |
|
V76652 | PD1-PDL1-IN 1 TFA | PD1-PDL1-IN 1 TFA (compound 16) is a potent programmed cell death 1 (PD-1) inhibitor. | |
|
V76646 | Pembrolizumab (anti-PD-1) | Pembrolizumab (anti-PD-1) is a humanized IgG4 antibody, an inhibitor (blocker/antagonist) of PD-1, and may be used in cancer immunity research. | |
|
V34656 | PROTAC PD-1/PD-L1 degrader-1 | 2447066-37-5 | PROTAC PD-1/PD-L1 degrader-1 (P22) is a novel First-in-class PD-L1 degrader based on PROTAC technology. |
|
V81254 | Pucotenlimab (HX008) | Pucotenlimab (HX008) is a humanized immunoglobulin G4 (IgG4) anti-programmed cell death protein 1 (anti-PD-1) monoclonal antibody (mAb). | |
|
V81462 | Sudubrilimab (HS636) | Sudubrilimab (HS636) is an Ig G1-kappa monoclonal antibody (mAb) directed against PDL1. | |
|
V60030 | Sulfosuccinimidyl Oleate | 135661-44-8 | Sulfosuccinimidyl oleate (SSO) is along chain fatty acid acting as an irreversible inhibitor of the fatty acid translocase CD36 with anti-inflammatory effects. |
|
V60029 | Sulfosuccinimidyl Oleate sodium | 1212012-37-7 | Sulfosuccinimidyl oleate sodium (SSO sodium salt) is along chain fatty acid acting as an irreversible inhibitor of the fatty acid translocase CD36, blocking uptake of oleate, linoleate, or stearate by about 65% when added at 200 µM to adipocytes. |
|
V81603 | TPP-1 TFA | TPP-1 TFA is a potent inhibitor of PD-1/PD-L1 interaction. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
